Abstract
MDL 26,024GO was shown to be an orally absorbed mediator release inhibitor in the rat PCA and PPA tests. In addition, the compound was shown to both elicit and inhibit elicitation of the Bezold-Jarisch reflex in the dog. MDL 26,024GO also significantly reducedAscaris-induced changes in pulmonary mechanics in cynomolgus monkeys. The compound inhibited both early and late phase antigen induced-changes inAscaris-sensitive sheep, as well as the increased airway hyperreactivity which normally follows antigen challenge. These results suggest the compound may have therapeutic potential in the treatment of asthma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
N. Peet, L. Baugh, S. Sunder, J. Lewis, E. Matthews, E. Olberding and D. Shah,3-(1H-tetrazol-5-yl)-4(3H)-quinazolinone Sodium Salt (MDL 427): A new antiallergic agent. J. Med. Chem.29, 2403–2409 (1986).
H. Cairns, D. Cox, K. Gould, A. Ingall and J. Suschitzky,New antiallergic pyrano [3,2-g]quinolin-2,8-dicarboxylic acids with potential for the topical treatment of asthma. J. Med. Chem.28, 1832–1842 (1985).
W. Abraham, J. Delehunt, L. Yerger and B. Marchette,Characterization of a late phase pulmonary response after an antigen challenge in allergic sheep. Am. Rev. Respir. Dis.128, 839–844 (1983).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Baugh, L., Abraham, W., Matthews, E. et al. Pharmacological profile of MDL 26,024GO: A novel antiasthmatic agent. Agents and Actions 27, 431–434 (1989). https://doi.org/10.1007/BF01972843
Issue Date:
DOI: https://doi.org/10.1007/BF01972843